The authors enrolled a cohort of COVID-19 recovered participants and developed neutralisation assays to examine their antibody responses. These results were then used in an existing high-throughput antibody generation pipeline to rapidly screen over 1800 antibodies, which were then tested in an animal model. The authors were able to isolate potent neutralising antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. They found that passive transfer of these nAbs provides protection against disease following high-dose SARS-CoV-2 challenge in Syrian hamsters; allowing them to maintain their weight and have low lung viral titres. This suggests that nAbs could be used for prophylaxis, and potentially therapy, of COVID-19.
Read more here